Highlights Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
13.41 ^USD	-2.76%		+5.92%	-25.95%

05-07	Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating	MT
05-07	RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	03-12	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	02-04	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	26/09/23	CI
Earnings Flash (PLRX) PLIANT THERAPEUTICS Reports Q2 Revenue $248,000	09/08/23	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	09/08/23	CI
Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress	23/06/23	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures	30/04/23	CI
Pliant Therapeutics Starts Bexotegrast Enrollment at Higher Dose in Primary Sclerosing Cholangitis Trial	13/03/23	MT
Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis	13/03/23	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI
Pliant Therapeutics, Inc. Announces 24-Week Data from the 320 mg Dose Group of the INTEGRIS-IPF Phase 2a Trial in Patients with IPF is Expected in the Second Quarter of 2023	09/03/23	CI
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/03/23	CI
Earnings Flash (PLRX) PLIANT THERAPEUTICS Reports Q4 Revenue $1.97M	09/03/23	MT
Novartis to End Collaboration Agreement with Pliant Pharmaceuticals for PLN-1474	24/02/23	MT
Pliant Therapeutics, Inc. Announces Termination of Material Definitive Agreement	23/02/23	CI
Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors	02/02/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Highlights

Filters